Update on infliximab: An intravenous biologic therapy for psoriasis

Expert Review of Dermatology

Volumn 2, Issue 6, 2007, Pages 707-713

  Pearce, Daniel J ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Biologics; Infliximab; Psoriasis; TNF; TNF ; Treatment

Indexed keywords

ABT 874; ADALIMUMAB; ALEFACEPT; AZATHIOPRINE; CYCLOSPORIN; DIPHENHYDRAMINE; EFALIZUMAB; ETANERCEPT; ETRETIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LIVER ENZYME; METHOTREXATE; MONOCLONAL ANTIBODY; PARACETAMOL; PLACEBO; PREDNISONE; PURINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; USTEKINUMAB;

ABDOMINAL PAIN; ADJUVANT THERAPY; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CANDIDIASIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DIARRHEA; DISEASE SEVERITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENTERITIS; ERYTHEMA MULTIFORME; FATIGUE; FIBROSING ALVEOLITIS; GUILLAIN BARRE SYNDROME; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; LIVER TOXICITY; LONG TERM CARE; LUPUS LIKE SYNDROME; MYELITIS; NAUSEA; NEUROPATHY; NEUTROPENIA; OFF LABEL DRUG USE; PAIN; PATIENT MONITORING; PERICARDIAL EFFUSION; PHARMACODYNAMICS; PHARYNGITIS; PHOTOTHERAPY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RHEUMATOID ARTHRITIS; RHINITIS; SEPSIS; SIDE EFFECT; SINUSITIS; STEVENS JOHNSON SYNDROME; SYSTEMIC VASCULITIS; T CELL LYMPHOMA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VASCULITIS; VIRUS REACTIVATION;

EID: 37349094379     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.2.6.707     Document Type: Article

References (42)

1. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin. Exp. Dermatol. 26(4), 314-320 (2001).
2. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm. Venereol. 80(6), 430-434 (2000).
3. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. 41(3 Pt 1), 401-407 (1999).
4. Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR. The negative impact of psoriasis on the workplace. J. Dermatolog. Treat. 17(1), 24-28 (2006).
5. Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin. Pharmacother. 4(9), 1525-1533 (2003).
6. Stern RS. Inpatient hospital care for psoriasis: a vanishing practice in the United States. J. Am. Acad. Dermatol. 49(3), 445-450 (2003).
7. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 137(3), 280-284 (2001).
8. Krueger GG, Langley RG, Leonardi C et al. A human interleukin-12/ 23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356 (6), 580-592 (2007).
9. Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am. J. Med. 107(6), 595-605 (1999).
10. Pardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: an algorithm-based approach for primary care physicians. Am. Fam. Physician 61(3), 725-733, 736 (2000).
11. Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J. Am. Acad. Dermatol. 41(3 Pt 2), S25-S28 (1999).
12. Feldman S. Advances in psoriasis treatment. Dermatol. Online J. 6(1), 4 (2000).
13. Gordon PM, Diffey BL, Matthews JN, Farr PM. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J. Am. Acad. Dermatol. 41(5 Pt 1), 728-732 (1999).
14. Yones SS, Palmer RA, Garibaldinos TT, Hawk JL. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch. Dermatol. 142(7), 836-842 (2006).
15. Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N. Engl. J. Med. 349(7), 658-665 (2003).
16. Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J. Dermatolog. Treat. 17(1), 29-37 (2006).
17. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J. Am. Acad. Dermatol. 55(5), 829-835 (2006).
18. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 296(14), 1735-1741 (2006).
19. Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br. J. Dermatol. 139(1), 88-95 (1998).
20. Shupack J, Abel E, Bauer E et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J. Am. Acad. Dermatol. 36(3 Pt 1), 423-432 (1997).
21. Ho VC, Griffiths CE, Berth-Jones J et al. Intermittent short courses of cyclosporine microesnulsion for the long-term management of psoriasis: a 2-year cohort study. J. Am. Acad. Dermatol. 44(4), 643-651 (2001).
22. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. New treatments for psoriasis: which biologic is best? J. Dermatolog. Treat. 17 (2), 96-107 (2006).
23. Papp KA, Tyring S, Lahfa M et al. A global Phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 152 (6), 1304-1312 (2005).
24. Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J. Am. Acad. Dermatol. 55(4), 598-606 (2006).
25. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet 366(9494), 1367-1374 (2005).
26. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An International, randomized, double-blind, placebo-controlled Phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. Dermatol. 139(6), 719-727 (2003).
27. Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290(23), 3073-3080 (2003).
28. Knight DM, Trinh H, Le J et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30(16), 1443-1453 (1993).
29. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 7(3), 251-259 (1995).
30. Centocor. Remicade (infliximab), package insert (2007).
31. Wolbink GJ, Vis M, Lems W et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 54(3), 711-715 (2006).
32. Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J. Rheumatol. 33(1), 31-36 (2006).
33. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 54(12), 3782-3789 (2006).
34. Poulalhon N, Begon E, Lebbe C et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br. J. Dermatol. 156(2), 329-336 (2007).
35. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 51(4), 534-542 (2004).
36. Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J. Am. Acad. Dermatol. 56(1), 31-15 (2007).
37. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 52(4), 1227-1236 (2005).
38. Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin. Gastroenterol. Hepatol. 5(6), 729-735 (2007).
39. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 44(2), 265-267 (2007).
40. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19), 2275-2285 (2006).
41. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J. Am. Acad. Dermatol. 56(1), e55-e79 (2007).
42. Feldman SR, Gordon KB, Bala M et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br. J. Dermatol. 152(5), 954-960 (2005).